The vascular endothelial growth factor (VEGF) pathway is well established as one of the key regulators of this process. The VEGF/VEGF-receptor axis is composed of multiple ligands and receptors with ...

Panelists discuss how higher-dose and dual-pathway anti-VEGF agents enable longer intervals, improved fluid control, and more flexible treatment strategies across retinal vascular diseases.

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has shared an update. Shanghai Henlius Biotech has initiated a first-in-human phase 1 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. PARK CITY, Utah — In this Healio Video Perspective from ...

Direct anti-VEGF angiogenic agents were a strong risk factor for high-grade hypertension, and multikinase inhibitors for high-grade proteinuria. Vascular endothelial growth factor signaling pathway ...

Science Progress (1933-), Vol. 104, No. 3 (2021), pp. 1-14 (14 pages) Hepatocellular carcinoma is one of the leading causes of malignant tumor related death word wide with poor prognosis. Chemotherapy ...

Summit Therapeutics specializes in developing innovative therapeutic solutions for oncology and infectious diseases. Their flagship drug candidate, Ivonescimab, is in phase 3 clinical trials and shows ...

Please provide your email address to receive an email when new articles are posted on . Bispecifics are a relatively new area in ophthalmology. In 2022, faricimab was the first-ever FDA-approved ...

– Data support casdozo as a promising novel immuno-oncology agent with clinical activity in liver cancer that may be associated with IL-27 pathway biomarkers – – Data support continued evaluation of ...

BioNTech is shelling out $800 million upfront to acquire China-based Biotheus in a move that would give it access to a late-stage oncology bispecific antibody, the drugmaker announced Wednesday. The ...